tetano
Editor, Senior Moderator
Sci Rep. 2017 Mar 21;7:44839. doi: 10.1038/srep44839.
[h=1]Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.[/h] Yang J[SUP]1[/SUP], Shim SM[SUP]2,[/SUP][SUP]3[/SUP], Nguyen TQ[SUP]1,[/SUP][SUP]4[/SUP], Kim EH[SUP]2,[/SUP][SUP]5[/SUP], Kim K[SUP]6[/SUP], Lim YT[SUP]7[/SUP], Sung MH[SUP]6,[/SUP][SUP]8[/SUP], Webby R[SUP]9[/SUP], Poo H[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8[SUP]+[/SUP] T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.
PMID: 28322289 PMCID: PMC5359587 DOI: 10.1038/srep44839
Free full text
[h=1]Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine.[/h] Yang J[SUP]1[/SUP], Shim SM[SUP]2,[/SUP][SUP]3[/SUP], Nguyen TQ[SUP]1,[/SUP][SUP]4[/SUP], Kim EH[SUP]2,[/SUP][SUP]5[/SUP], Kim K[SUP]6[/SUP], Lim YT[SUP]7[/SUP], Sung MH[SUP]6,[/SUP][SUP]8[/SUP], Webby R[SUP]9[/SUP], Poo H[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, the global outbreak of an influenza pandemic emphasized the need for an effective vaccine adjuvant. In this study, we examined the efficacy of poly-γ-glutamic acid/chitosan (PC) nanogel as an adjuvant for the influenza vaccine. PC nanogel significantly enhanced antigen-specific cross-presentation and cytotoxic T lymphocyte (CTL) activity. Compared with alum, the protective efficacy of the pandemic H1N1 influenza (pH1N1) vaccine was substantially increased by PC nanogel, with increased hemagglutination-inhibition titers, CTL activity, and earlier virus clearance after homologous and heterosubtypic [A/Philippines/2/82 (H3N2)] virus challenges. However, CD8[SUP]+[/SUP] T cell-depleted mice displayed no protection against the heterosubtypic virus challenge after immunization with PC nanogel-adjuvanted pH1N1 vaccine. We also observed that using PC nanogel as a vaccine adjuvant had a dose-sparing effect and significantly enhanced the long-lasting protection of the pH1N1 vaccine. Together, these results suggest that PC nanogel is a promising vaccine adjuvant that could broadly prevent influenza virus infection.
PMID: 28322289 PMCID: PMC5359587 DOI: 10.1038/srep44839
Free full text